Animal only
This rat study investigated whether BPC 157, a synthetic pentadecapeptide derived from a gastric protein, could protect skeletal muscle tissue from ischemia-reperfusion (I/R) injury. Twenty-four male Wistar rats were divided into four groups (n=6 each): sham surgery, BPC 157 alone, I/R injury alone, and I/R injury treated with BPC 157. I/R was induced by clamping the abdominal aorta for 45 minutes followed by 2 hours of reperfusion; BPC 157 was given intraperitoneally at the end of the ischemia period. The study measured oxidative stress markers (MDA, SOD, TAS, TOS) in serum, gene expression of inflammatory and apoptotic markers (IL-6, HIF-1α, p53, Bcl-2, Bax, Caspase-3) via qRT-PCR, and protein expression (VEGF, eNOS, IL-6, Caspase-3) via immunohistochemistry, alongside histopathological scoring. The authors report that I/R increased oxidative stress, inflammation, and apoptotic signaling, while BPC 157 treatment was associated with reduced oxidative markers, decreased inflammatory and pro-apoptotic gene expression, increased anti-apoptotic Bcl-2, partial restoration of VEGF, and improved muscle histology. Limitations include very small group sizes (n=6), use of a single dose, a single species, and no human data, restricting the generalizability of findings.
Scientific reports · May 2026DOI ↗ Animal only
This review paper examines the preclinical and limited clinical evidence surrounding Body Protective Compound-157 (BPC-157), a synthetic pentadecapeptide derived from gastric proteins. The authors summarize experimental findings across a range of tissue types, noting that BPC-157 appears to support angiogenesis, collagen synthesis, fibroblast activity, and nitric oxide pathway modulation in animal models, with reported benefits to muscle, tendon, ligament, bone, and gastrointestinal healing. Anti-inflammatory effects, including reduced cytokine activity and improved microvascular integrity, as well as pain modulation via peripheral and dopaminergic mechanisms, are also described. The review notes that human research is limited to small pilot studies in musculoskeletal pain, interstitial cystitis, and intravenous administration contexts, with no major adverse effects reported. The authors acknowledge significant limitations: inconsistent preparation standards, lack of rigorous controlled trials, limited clinical validation, and ongoing regulatory restrictions. The paper concludes that BPC-157 represents a promising candidate for regenerative medicine but that robust clinical evidence is needed before therapeutic use can be recommended. As a narrative review drawing primarily on animal data, it does not establish efficacy in humans.
International journal of molecular sciences · Mar 2026DOI ↗ Animal only
This review paper examines the potential therapeutic role of BPC 157 (a synthetic 15-amino-acid peptide derived from a gastric protein) in treating severe electrolyte disturbances, drawing on a collection of animal and in-vitro experiments. The paper covers four electrolyte scenarios: (1) hyperkalemia — where BPC 157 was reported to counteract KCl overdose effects including arrhythmias, hypertension, sphincter dysfunction, and mortality in rat models; (2) hypokalemia — where BPC 157 administration (both prophylactically and therapeutically) was reported to prevent fatal outcomes, ECG abnormalities, AV block, and skeletal muscle myoclonus in furosemide-treated rats; (3) hypermagnesemia — where BPC 157 appeared to alleviate muscle weakness, brain lesions, and secondary hyperkalemia in rats; and (4) lithium intoxication — where BPC 157 was reported to promote collateral vascular pathways and resolve multiorgan failure features. In-vitro experiments using HEK293 cells suggested BPC 157 can modulate membrane potential changes induced by electrolyte imbalances. Key limitations include reliance on animal and cell-based data with no human clinical trials reported, and the review format limits independent assessment of individual study methodologies.
Current neuropharmacology · Mar 2026DOI ↗ Animal only
This review paper proposes cytoprotection as a unifying therapeutic framework to address what the authors call the "hemorrhage-thrombosis paradox" — the clinical challenge that hemorrhage and thrombosis can coexist as phase-dependent manifestations of vascular dysregulation. The paper centers on BPC 157, a stable synthetic gastric pentadecapeptide, which the authors argue can simultaneously counteract both hemorrhage and thrombosis in rodent models without directly interfering with the coagulation cascade (as assessed by aggregometry and thromboelastometry). The review synthesizes preclinical and conceptual evidence to argue that BPC 157 achieves this bidirectional vascular regulation through preservation of endothelial integrity, normalization of microcirculation, modulation of the nitric oxide system, and recruitment of collateral adaptive pathways. The authors contrast this proposed "full cytoprotection" with the "partial cytoprotection" of conventional agents such as anticoagulants, antiplatelet drugs, fibrinolytics, beta blockers, calcium channel blockers, and statins, which they contend act in isolated or unidirectional ways. The paper also discusses applications in wound healing, arrhythmia control, and normalization of Virchow's triad. Notably, the authors explicitly acknowledge that findings are predominantly preclinical and that clinical validation in humans remains necessary.
Pharmaceuticals (Basel, Switzerland) · Mar 2026DOI ↗ Animal only
This systematic review examines the use of platelet-rich plasma (PRP), growth factors (PDGF, TGF-β1, IGF-1, FGF, VEGF, BMPs), and the stable gastric pentadecapeptide BPC 157 in the treatment of tendon, ligament, and muscle injuries, as well as osteotendinous, myotendinous, and muscle-to-bone junction injuries. The authors frame these interventions under the concept of "cytoprotection," emphasizing restoration of tissue integrity. The review concludes that while growth factors delivered locally via carriers show improvements in tendon, ligament, and muscle healing, some (PDGF, TGF-β1, IGF-1) appear to have limited benefit in muscle lesions, and all show limited or no efficacy at junctional healing sites. By contrast, the authors argue that BPC 157 — proposed as a cytoprotection mediator — demonstrated consistent efficacy across tendon, ligament, muscle, and junctional injuries in rat studies, via both systemic (intraperitoneal, intragastric, drinking water) and local (topical cream) administration, without requiring carriers or scaffolds. The authors suggest translational potential for clinical use and call for further clinical trials. Key limitations include that the supporting evidence for BPC 157 is derived almost exclusively from preclinical (rat) studies, with no human clinical trial data presented.
Pharmaceuticals (Basel, Switzerland) · Feb 2026DOI ↗ Animal only
This review paper proposes "cytoprotection" as a conceptual framework for evaluating antiarrhythmic drugs — defined as the ability to suppress arrhythmias while avoiding adverse electrophysiological or systemic effects. The authors systematically compare conventional antiarrhythmics (Classes I–IV) and newer agents (late INa inhibitors, IKs enhancers, RyR2 stabilizers, gap junction modulators, and atrial-selective antiarrhythmics), characterizing them as offering only partial cytoprotection over a narrow-to-moderate range. By contrast, the stable gastric pentadecapeptide BPC 157 is hypothesized to offer broader, "full-range" cytoprotective-antiarrhythmic effects. The authors cite preclinical rodent studies showing BPC 157 restoring sinus rhythm, normalizing ECG intervals, preventing AV block, suppressing ventricular tachycardia, and attenuating ST-segment changes across diverse arrhythmia models (hypo-/hyperkalemia, ischemia-reperfusion, drug-induced). In vitro HEK293 cell data reportedly show direct membrane-stabilizing actions. The authors acknowledge that human clinical data on BPC 157 remain limited and non-cardiac in nature, and explicitly call for translational clinical investigation. The paper's central claims about BPC 157 in arrhythmias rest almost entirely on preclinical and in vitro evidence, with no controlled human cardiac trials reported.
Pharmaceuticals (Basel, Switzerland) · Jan 2026DOI ↗ Animal only
This rat study used Fourier Transform Infrared (FTIR) spectroscopy to investigate how the stable gastric pentadecapeptide BPC 157 affects aortic wall composition following unilateral adrenalectomy. Abdominal aortas were collected from rats at three time points (15 minutes, 5 hours, and 24 hours) after surgery. BPC 157 was administered intragastrically immediately following the procedure. Spectral data were analyzed using principal component analysis (PCA) and support vector machine discriminant analysis (SVMDA). The study found that BPC 157-treated animals showed clear and reproducible spectral separation from controls at all time points, with the most notable differences in amide I and amide II bands (associated with protein secondary structure, including collagen and elastin) and lipid C-H stretching bands (associated with membrane integrity). The authors interpreted these signatures as consistent with early extracellular matrix reinforcement and membrane preservation in the vascular wall. Limitations include the exclusive use of an animal model, a small number of time points, and the indirect, spectroscopic nature of the outcome measures, which do not constitute direct functional or histological endpoints. No human data were reported.
Pharmaceuticals (Basel, Switzerland) · Jan 2026DOI ↗ Animal only
This 7-day rat study investigated the course of surgically created tracheocutaneous fistulas and whether the pentadecapeptide BPC 157 could promote healing, with a focus on the nitric oxide (NO) system's role. Rats with tracheocutaneous fistulas displayed severe respiratory distress, including open-mouth breathing, abdominal "heaving," cyanosis, abundant fistula secretion, weight loss, failed skin and tracheal wound healing, a well-formed fistulous tract, and tracheal shrinking below the fistula site. Tissue analyses showed decreased NO levels and increased malondialdehyde (MDA), a marker of oxidative stress. BPC 157, administered either intraperitoneally or in drinking water, was reported by the authors to accelerate fistula closure, improve macro- and microscopic healing of skin and tracheal defects, reduce respiratory distress signs, and counteract the NO and MDA changes observed in untreated controls. Using a "triple NO-agent" approach (L-NAME to block NO synthesis, L-arginine to enhance it, or both combined), the study further reported that BPC 157 could override L-NAME-induced worsening, enhance L-arginine-induced improvement, and restore healing even under combined NO immobilization. Key limitations include the exclusive use of an animal model, small experimental groups typical of rat studies, and the absence of human data.
Pharmaceuticals (Basel, Switzerland) · Jan 2026DOI ↗ Animal only
This paper introduces a novel conceptual framework called the "triad" — linking corneal ulcer healing, corneal neovascularization, and intraocular pressure — and extends it to avascular tissue healing, using tendon as a parallel model. The authors propose cytoprotection as a unifying therapeutic principle and use the stable gastric pentadecapeptide BPC 157 as a primary illustrative agent. Drawing on preclinical studies, the paper describes findings in which BPC 157 reportedly normalized elevated intraocular pressure in glaucomatous rats, preserved retinal integrity, restored pupil function, maintained corneal transparency during ulcer or abrasion healing, and counteracted corneal neovascularization and dry eye. The paper also systematically maps a broad range of existing standard therapeutic agents — including ascorbate, fibronectin, EGF, anti-VEGF agents, corticosteroids, prostaglandin analogs, and Rho-kinase inhibitors — onto this triad to highlight shared pathways and inconsistencies across drug classes. The work is framed as a theoretical and narrative synthesis of preclinical data rather than a new clinical trial, and the authors explicitly call for further translational research before clinical application. Key limitations include the absence of human trial data and reliance on animal models.
Pharmaceuticals (Basel, Switzerland) · Nov 2025DOI ↗ Animal only
This paper is a commentary responding to a previously published literature and patent review by Józwiak et al. (Pharmaceuticals 2025) that raised concerns about BPC 157, a stable synthetic gastric pentadecapeptide. The authors defend BPC 157's therapeutic profile, arguing that the reviewed concerns — specifically that it promotes pathological angiogenesis, elevates nitric oxide (NO) and eNOS toward damaging free radical formation, and may contribute to tumorigenesis or neurodegenerative diseases — are speculative and contradicted by existing preclinical evidence. The authors frame BPC 157 as a cytoprotective agent rooted in Robert's and Szabo's cytoprotection concept, emphasizing its alleged pleiotropic effects across organ systems. They argue that BPC 157 modulates rather than indiscriminately amplifies angiogenesis and the NO system, citing animal model studies on wound healing, corneal transparency, anti-tumor effects (per Folkman's concept), and counteraction of Parkinson's- and Alzheimer's-like disturbances in mice and rats. The paper reports a high safety profile (LD50 not achieved in animal studies). Key limitations include that this is a narrative commentary relying heavily on preclinical data, with no new human clinical trial data presented and no controlled experimental methodology introduced.
Pharmaceuticals (Basel, Switzerland) · Sep 2025DOI ↗ Animal only
This review paper examines the proposed therapeutic mechanisms and safety profile of BPC 157, a synthetic 15-amino-acid peptide derived from a gastric protein. The authors argue, drawing on Robert and Szabo's cytoprotection concept, that BPC 157's protective effects on gastric epithelial and endothelial cells extend to other organ systems (cytoprotection → organoprotection). The paper addresses and disputes concerns that BPC 157 might promote tumorigenesis through angiogenesis, generate harmful free radicals via increased nitric oxide (NO) and eNOS activity, or contribute to neurodegenerative diseases such as Parkinson's and Alzheimer's. Instead, the authors contend that, based on reviewed animal and in vitro studies, BPC 157 modulates angiogenesis in a context-dependent manner—maintaining corneal transparency and opposing pathological neovascularization—while demonstrating anti-tumor effects both in vivo and in vitro per Folkman's framework. The paper also reports that BPC 157 counteracts Parkinson's- and Alzheimer's-like disturbances in rodent models and modulates NO levels without promoting damaging free radical formation. Key limitations include the heavy reliance on animal and in vitro data, the absence of human clinical trial data, and the authors' advocacy framing.
Pharmaceuticals (Basel, Switzerland) · Jun 2025DOI ↗ Animal only
This review paper examines pharmacotherapies for abdominal compartment syndrome (ACS) and intra-abdominal hypertension (IAH) through the lens of cytoprotection theory, framing these conditions as failures of cytoprotective mechanisms. The authors survey existing pharmacological agents used in ACS/IAH management, noting that most currently reported treatments are limited in scope—typically effective in only one organ, tested only in mild-to-moderate IAH, applied prophylactically rather than therapeutically, and lacking confirmed broad effectiveness. The review then focuses on stable gastric pentadecapeptide BPC 157 as a proposed cytoprotective agent with claimed pleiotropic effects. The authors argue that BPC 157 may address multiple simultaneous targets in ACS/IAH, including compression/ischemia and decompression/reperfusion injury across several organs (brain, heart, lung, liver, kidney, gastrointestinal tract). A proposed mechanism involving activation of collateral "bypassing" vascular pathways—particularly azygos vein blood flow—is described as a potential key to counteracting multiorgan failure, vascular dysfunction, thrombosis, and free radical damage. The paper is a narrative review drawing primarily on animal study data; it does not present original clinical trial data or human evidence. Conclusions about BPC 157 efficacy are therefore speculative in a human clinical context.
Pharmaceuticals (Basel, Switzerland) · Jun 2025DOI ↗ Animal only
This rat study investigated whether the stable gastric pentadecapeptide BPC 157, administered orally, could promote reattachment of the quadriceps muscle to bone following surgical detachment in rats. The model involved both complete detachment of the rectus femoris muscle and partial detachment of the vastus muscles. Untreated control animals exhibited persistent healing failure, including impaired walking and permanent knee flexure across all observation time points (1 day through 90 days post-injury). In contrast, animals receiving oral BPC 157 (at two dose levels) showed consistent improvement across macro- and microscopic analysis, ultrasound, MRI, biomechanical testing, and functional walking assessments. The authors report that treated animals showed early muscle-to-bone approximation, elimination of leg contracture, and progressive tissue reorganization, including periosteal reactivation and mesenchymal cell proliferation by day 3, and well-organized cortical bone with mature, parallel-oriented muscle fibers by 3 months. Key limitations include exclusive use of an animal model with no human data, lack of blinding details, and relatively small group sizes typical of preclinical peptide research. The findings are attributed solely to the study authors and do not establish clinical efficacy or safety in humans.
Pharmaceutics · Jan 2025DOI ↗ Animal only
This review paper examines the published preclinical evidence on stable gastric pentadecapeptide BPC 157 as a potential therapeutic agent for intestinal anastomoses and related gastrointestinal conditions in rat models. The authors summarize findings across a range of anastomosis types — including esophagogastric, colocolonic, jejunoileal, and ileoileal — and report that BPC 157 therapy was associated with improved healing outcomes in these animal studies. The review also covers concomitant gastrointestinal disturbances such as esophagitis, sphincter dysfunction, colitis, short bowel syndrome, and major vessel occlusion, as well as dysfunction of the nitric oxide and prostaglandin systems. Additionally, the authors discuss fistula healing (e.g., colocutaneous, gastrocutaneous, vesicovaginal, rectovaginal) as a related phenomenon, framing fistulas as abnormal anastomoses between tissues. The review concludes that both anastomoses and fistulas showed healing responses attributed to BPC 157 in rat models. Limitations include the exclusive reliance on animal data, absence of human clinical trials, and the inherent interpretive limitations of a narrative review format. No controlled human evidence is presented or discussed.
Pharmaceuticals (Basel, Switzerland) · Aug 2024DOI ↗ Animal only
This review paper examines the proposed mechanisms underlying the wide-ranging (pleiotropic) biological effects of BPC 157, a synthetic 15-amino-acid peptide described as stable in human gastric juice. The authors attempt to frame BPC 157's observed effects within classical neurotransmitter criteria — including production, release, receptor interaction, and clearance — while acknowledging that direct conclusive evidence meeting these criteria is lacking. Instead, the paper compiles a network of interconnected preclinical evidence suggesting that BPC 157 may counteract disturbances across multiple neurotransmitter systems, including dopamine, serotonin, glutamate, GABA, adrenaline/noradrenaline, acetylcholine, and the nitric oxide (NO) system. The paper also discusses potential receptor interactions (e.g., VEGF and growth hormone receptors) and observations related to nerve-muscle and nerve-nerve relationships in various experimental models. The authors draw parallels between BPC 157's activity and gasotransmitter behavior. A key limitation explicitly noted by the authors is the absence of direct human clinical trial data; the evidence base relies predominantly on animal and in vitro studies. This paper does not establish clinical efficacy or safety in humans.
Pharmaceuticals (Basel, Switzerland) · Apr 2024DOI ↗